| You are here: Home: BCU 5|2002: Anthony Howell, BSc, MBBS, MSc, FRCP - Select Publications
Select Publications
Use of bisphosphonates in breast cancer
Ali SM et al. Safety and efficacy of bisphosphonates beyond
24 months in cancer patients. J Clin Oncol 2001;19:3434-7.
Abstract
Berenson JR. Zoledronic acid in cancer patients with bone
metastases: Results of Phase I and II trials. Semin Oncol
2001;28:25-34. Abstract
Bryce CJ et al. Does short-term, intravenous, low-dose
clodronate, administered with adjuvant chemotherapy for premenopausal
breast cancer, reduce bone loss in the first year in patients? Proc
ASCO 2002;Abstract
270.
Chlebowski RT. Factors influencing the role of bisphosphonates
in breast cancer management. Semin Oncol 2001;28:42-8.
Abstract
Coleman RE. Should bisphosphonates be the treatment of
choice for metastatic bone disease? Semin Oncol 2001;28:35-41.
Abstract
Coleman RE, Seaman JJ. The role of zoledronic acid in
cancer: Clinical studies in the treatment and prevention of bone
metastases. Semin Oncol. 2001;28:11-6. Abstract
Diel IJ. Bisphosphonates in the prevention of bone metastases:
Current evidence. Semin Oncol 2001;28:75-80. Abstract
Diel IJ, Mundy GR. Bisphosphonates in the adjuvant treatment
of cancer: Experimental evidence and first clinical results.
International Bone and Cancer Study Group (IBCG). Br J Cancer 2000;82:1381-6.
Abstract
Gralow JR. The role of bisphosphonates as adjuvant therapy
for breast cancer. Curr Oncol Rep 2001;3:506-15. Abstract
Hillner BE et al. American Society of Clinical Oncology
guideline on the role of bisphosphonates in breast cancer. American
Society of Clinical Oncology Bisphosphonates Expert Panel.
J Clin Oncol 2000;18:1378-91. Abstract
Hillner BE et al. Pamidronate in prevention of bone complications
in metastatic breast cancer: A cost-effectiveness analysis.
J Clin Oncol 2000;18:72-9. Abstract
Jagdev SP et al. The bisphosphonate, zoledronic acid,
induces apoptosis of breast cancer cells: Evidence for synergy with
paclitaxel. Br J Cancer 2001;84:1126-34. Abstract
Nikolic-Tomasevic Z et al. Tumor 'flare' hypercalcemia--an
additional indication for bisphosphonates? Oncology 2001;60:123-6.
Abstract
Paterson AH. Adjuvant bisphosphonate therapy: The future.
Semin Oncol 2001;28:81-5. Abstract
Perez EA. Metastatic bone disease in breast cancer: The
patient's perspective. Semin Oncol 2001;28:60-3. Abstract
Powles TJ et al. A randomised placebo controlled trial
to evaluate the effect of the bisphosphonate, clodronate, on the
incidence of metastases and mortality in patients with primary operable
breast cancer. Breast Cancer Res Treat 2001;Abstract
1.
Rosen LS et al. Zoledronic acid versus pamidronate in
the treatment of skeletal metastases in patients with breast cancer
or osteolytic lesions of multiple myeloma: A phase III, double-blind,
comparative trial. Cancer J 2001;7:377-87. Abstract
Saarto T et al. Adjuvant clodronate treatment does not
reduce the frequency of skeletal metastases in node-positive breast
cancer patients: 5-year results of a randomized controlled trial.
J Clin Oncol 2001;19:10-7. Abstract
Saarto T et al. The effect of clodronate and antioestrogens
on bone loss associated with oestrogen withdrawal in postmenopausal
women with breast cancer. Br J Cancer 2001;84:1047-51.
Abstract
Tripathy D. Bisphosphonates in oncology: Breast cancer
and beyond. Semin Oncol 2001;28:86-91. Abstract
Van Poznak C. How are bisphosphonates used today in breast
cancer clinical practice? Semin Oncol 2001;28:69-74. Abstract
Vehmanen L et al. Long-term impact of chemotherapy-induced
ovarian failure on bone mineral density (BMD) in premenopausal breast
cancer patients. The effect of adjuvant clodronate treatment.
Eur J Cancer 2001;37:2373-8. Abstract
Fulvestrant (ICI 182,780; Faslodex®)
Cheung KL, Robertson JF. Fulvestrant. Expert
Opin Investig Drugs 2002;11:303-308. Abstract
Curran M, Wiseman L. Fulvestrant. Drugs 2001;61:807-13;
discussion 814. Abstract
Elkak AE, Mokbel K. Pure antiestrogens and breast cancer.
Curr Med Res Opin 2001;17:282-9. Abstract
Erikstein B et al. ICI 182,780 (‘Faslodex’)
250 mg monthly intramuscular (IM) injection shows consistent PK
profile when given as either 1 x 5ml or 2 x 2.5 ml injections in
postmenopausal women with advanced breast cancer (ABC).
Proc ASCO 2001; Abstract
2025.
Howell A. Preliminary experience with pure antiestrogens.
Clin Cancer Res 2001;7:4369s-4375s; discussion 4411s-4412s. Abstract
Howell A et al. Comparison of efficacy and tolerability
of fulvestrant (Faslodex) with anastrozole (Arimidex) in postmenopausal
women with advanced breast cancer. Breast Cancer Res Treat
2000;64(1): No Link available.
Johnston SR. Fulvestrant (AstraZeneca). Curr
Opin Investig Drugs 2002;3(2):305-12. Abstract
Jones S. Fulvestrant (‘Faslodex®’) versus
anastrozole (‘Arimidex®’) for the treatment of advanced
breast cancer in postmenopausal women – safety update on the
combined analysis of two multicenter trials. Breast Cancer
Res Treat 2001;Abstract
455.
Mauriac L. Fulvestrant (‘Faslodex®’) is
effective in advanced breast cancer in postmenopausal patients with
visceral metastases: Comparison with anastrazole. Breast
Cancer Res Treat 2001; Abstract
452.
Osborne CK. A double-blind randomized trial comparing
the efficacy and tolerability of FaslodexTM (fulvestrant) with ArimidexTM
(anastrozole) in postmenopausal (PM) women with advanced breast
cancer (ABC). Breast Cancer Res Treat 2000;64(1): No link
available.
Osborne CK et al. Selective estrogen receptor modulators:
Structure, function and clinical use. J Clin Oncol 2000;18(17):3172-3186.
Abstract
Parker LM et al. Greater duration of response in patients
receiving fulvestrant (‘Faslodex’) compared with those
receiving anastrozole (‘Arimidex’). Proc ASCO
2002;Abstract
160.
Robertson JF. Estrogen receptor downregulators: New antihormonal
therapy for advanced breast cancer. Clin Ther 2002;24 Suppl
A:A17-30. Abstract
Robertson JFR. A comparison of the single-dose pharmacokinetics
(PK) of ‘Faslodex’ (fulvestrant) 250 mg when given as
either a one x 5-ml intramuscular (IM) injection or two x 2.5-ml
injections in postmenopausal (PM) women with advanced breast cancer
(ABC). Breast Cancer Res Treat 2000;No link available.
Rosenberg Z and RS et al. Is ICI 182,780 an antiprogestin
in addition to being an antiestrogen? Breast Cancer Res
Treat 2000;60:1-8. Abstract
Vergote I. Evidence of continued sensitivity to endocrine
agents in postmenopausal women with advanced breast cancer progressing
on fulvestrant (‘Faslodex®’) treatment. Breast
Cancer Res Treat 2001;Abstract
446.
|
